PMID: 2488083Jan 1, 1989Paper

How to digitalize and to maintain optimal digoxin levels in congestive heart failure

Cardiovascular Drugs and Therapy
C Lambert, J L Rouleau

Abstract

Due to the narrow therapeutic-to-toxic ratio of digoxin, numerous studies have been done to assess the optimal digoxin level in patients with congestive heart failure. A digoxin level of 0.7-1.5 ng/mL (or 0.9-2.0 nMol/L) is generally considered optimal, but even at these levels toxicity may occur in certain clinical situations such as severe pulmonary disease or when electrolyte or metabolic disturbances are present. The optimal daily maintenance dose of digoxin depends on the preparation given and can be calculated by the equation of Jelliffe, which is largely based on the creatinine clearance of the patient. The daily digoxin dose must also be adjusted to take into consideration disease processes or concomitant drug therapy that can alter the volume of distribution, the biotransformation, or the excretion of the drug.

References

Jan 1, 1977·Clinical Pharmacokinetics·E Iisalo
Aug 1, 1979·European Journal of Pharmacology·D D Ku, B R Lucchesi
Feb 4, 1978·British Medical Journal·G Ejvinsson
Apr 21, 1977·The New England Journal of Medicine·D ChopraC T Sawin
Oct 1, 1977·Annals of Internal Medicine·L H Green, T W Smith
Nov 4, 1976·The New England Journal of Medicine·D D Brown, R P Juhl
Dec 1, 1975·British Heart Journal·F Hagemeijer, E Van Houwe
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Aug 1, 1987·Cardiovascular Drugs and Therapy·A J MossT Therneau
Jan 1, 1988·Cardiovascular Drugs and Therapy·J N Lessem
Jan 1, 1988·Fundamental & Clinical Pharmacology·S CopurS Uğurlu
May 1, 1985·Journal of the American College of Cardiology·B Surawicz
Mar 1, 1985·The American Journal of Cardiology·J T BiggerK J Ferrick
Mar 1, 1966·Annals of Internal Medicine·J E Doherty, W H Perkins
May 1, 1974·Progress in Cardiovascular Diseases·L Resnekov
Apr 1, 1974·Annals of Internal Medicine·D T Mason
Sep 27, 1973·The New England Journal of Medicine·D J GreenblattT W Smith
Sep 1, 1972·The American Journal of Cardiology·B LownH Garrison
Sep 1, 1971·Journal of Chronic Diseases·R W Jelliffe
Jan 1, 1970·American Heart Journal·R H SellerC Swartz
Apr 1, 1970·American Heart Journal·G T NolaD C Harrison
Apr 1, 1970·The American Journal of Cardiology·R ZelisE Braunwald
Dec 1, 1970·The Journal of Clinical Investigation·T W Smith, E Haber
Apr 1, 1971·Circulation Research·S F VatnerE Braunwald
May 6, 1971·The New England Journal of Medicine·G A BellerW B Hood
Jul 1, 1969·Diseases of the Chest·R W Jelliffe
Jan 1, 1984·European Journal of Clinical Pharmacology·R A Barbarash
Oct 1, 1984·Annals of Internal Medicine·M H GaultL L Longerich
Jul 1, 1983·Clinical Pharmacokinetics·T H Lee, T W Smith
Jan 1, 1984·Clinical Pharmacology and Therapeutics·M H GaultM A Dawe
Mar 1, 1984·Journal of the American College of Cardiology·E B MadsenJ Ross
May 15, 1984·The American Journal of Cardiology·Y OyamaK Goto
Sep 1, 1982·Drugs·J T Bigger, E B Leahey
Dec 18, 1980·The New England Journal of Medicine·S B ArnoldK Chatterjee
Jan 24, 1981·British Medical Journal·J O MoyseyD A Chamberlain
Apr 1, 1983·Clinical Pharmacology and Therapeutics·G G BelzJ Matthews
Apr 1, 1983·Clinical Pharmacology and Therapeutics·S WaldorffE Steiness
Apr 14, 1983·The New England Journal of Medicine·M R PudekE Ling
Jan 1, 1983·British Journal of Clinical Pharmacology·T Jogestrand, R Nordlander
Mar 25, 1982·The New England Journal of Medicine·D C LeeE Haber
May 1, 1982·Circulation·H O KleinE Kaplinsky

❮ Previous
Next ❯

Citations

Nov 5, 2010·QJM : Monthly Journal of the Association of Physicians·A Vaz PérezM Rauchhaus
Nov 15, 1993·The Medical Journal of Australia·A Bobik

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.